

## Dr. Reddy's launches FINRID™ in India

### - Enters transdermal patch segment

**August 05, 2009, Hyderabad**

Dr. Reddy's Laboratories Ltd. (NYSE: RDY) has launched Finrid™ (Fentanyl Transdermal Patch) in India. Used in the management of severe to moderate pain, Finrid™ provides continuous systemic delivery of Fentanyl, a potent opioid analgesic for upto 72 hours. It is the first opioid transdermal patch to be developed in India.

Being a controlled substance, Finrid™ will be sold through an independent distribution structure and will be available across hospitals and palliative care centers in India.

Finrid™ is available in a transdermal patch form, and delivers dosages of 25 mcg/hr and 50 mcg/hr depending on the patch used.

#### Notes to the editor:

Brief mode of action of Finrid™:

- A Transdermal Patch is a medicated adhesive patch that is placed on the skin to deliver a specific amount of drug through the skin and into the bloodstream.
- One of the many advantages over transdermal drug delivery is that it provides a long lasting controlled release of the drug into the patient.
- The transdermal patches would provide pain relief especially in targeted patients who have chronic pain suffering from cancer, rheumatoid arthritis among other problems.
- The product has been in-licensed from Sparsha Pharma.

#### Disclaimer

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

#### About Dr. Reddy's

Established in 1984, Dr. Reddy's Laboratories (NYSE: RDY) is an emerging global pharmaceutical company. We fulfill our purpose of providing affordable and innovative medicines through three core businesses: Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products. Our products are marketed globally, with a focus on India, US, UK, Germany and Russia.

[www.drreddys.com](http://www.drreddys.com)

*For more information please contact:*

#### Investors and Financial Analysts:

Kedar Upadhye at [kedar@drreddys.com](mailto:kedar@drreddys.com) / +91-40-66834297

Raghavender R at [raghavenderr@drreddys.com](mailto:raghavenderr@drreddys.com) / +91-40-66511529

Milan Kalawadia (USA) at [mkalawadia@drreddys.com](mailto:mkalawadia@drreddys.com) / +1- 908-203-4931

#### Media:

M Mythili at [mythilim@drreddys.com](mailto:mythilim@drreddys.com) / +91-40-66511620

S Rajan at [rajans@drreddys.com](mailto:rajans@drreddys.com) / +91-40- 66511725